Repositorio Dspace

One-year multicenter prospective real-world study of vericiguat effectiveness and safety in Spain

Mostrar el registro sencillo del ítem

dc.contributor.author Esteban-Fernández, Alberto
dc.contributor.author Calvo-Bernal, Beatriz
dc.contributor.author López-Vilella, Raquel
dc.contributor.author de-Lara, Gregorio
dc.contributor.author Belarte-Tornero, Laia-C
dc.contributor.author Barrantes-Castillo, Moisés
dc.contributor.author Gómez-Otero, Inés
dc.contributor.author Núñez-Villota, Julio
dc.contributor.author Robles-Gamboa, Carolina
dc.contributor.author López-Aguilera, José
dc.contributor.author Torremocha-López, Ana
dc.contributor.author Melendo-Viu, María
dc.contributor.author Simón-Ramón, Clara
dc.contributor.author Fluvia-Burgues, Paula
dc.contributor.author Pastor-Pérez, Francisco-José
dc.contributor.author Alonso-Salinas, Gonzalo
dc.contributor.author García-Pinilla, José-Manuel
dc.contributor.author Pomares-Varo, Antonia
dc.contributor.author Gayan-Ordas, Jara
dc.contributor.author González-Calle, David
dc.contributor.author Díez-Villanueva, Pablo
dc.contributor.author Galvan-Ruiz, Mario
dc.contributor.author Ortiz-Cortes, Carolina
dc.contributor.author Caravaca-Pérez, Pedro
dc.contributor.author Goena-Vives, Cristina
dc.contributor.author Seller, Julia
dc.contributor.author Jiménez-Blanco, Marta
dc.contributor.author Codina, Pau
dc.contributor.author Vietiez, José-María
dc.contributor.author Jordan-Martínez, Laura
dc.contributor.author López-Lluva, María-Thiscal
dc.contributor.author Mena-Sebastia, Elisabet
dc.contributor.author Pajaro, Pedro
dc.contributor.author Recio-Mayoral, Alejandro
dc.date.accessioned 2026-09-17T12:13:37Z
dc.date.available 2026-09-17T12:13:37Z
dc.date.issued 2026-05-05
dc.identifier.issn 2055-5822
dc.identifier.uri https://sms.carm.es/ricsmur/handle/123456789/28106
dc.description.abstract AIMS: To evaluate the effectiveness and safety of vericiguat in patients with heart failure and reduced ejection fraction (HFrEF) following recent decompensation in routine clinical practice in Spain. METHODS: VERISEC is a prospective, multicentre registry of 835 consecutive patients initiating vericiguat at 41 centres in Spain. Functional class, biochemical markers, ventricular function, and clinical events were analysed during a 1-year follow-up. RESULTS: Patients (age 71.3 years [SD: 11.2], 78.9% male) received highly optimized baseline therapy: 91.5% SGLT2i, 90.7% beta-blockers, 85.4% RAASi, and 79.8% MRAs. Quadruple therapy remained stable (61.7% baseline to 63.0% at 12 months; P = .526). At 1-year follow-up, significant improvements were observed. NT-proBNP decreased from 3532.0 (IQR: 1689.3-6974.5) to 2291.5 pg/ml (IQR: 1063.0-5076.3; P < .001) and LVEF increased from 30.3% (SD: 7.6) to 35.4% (SD: 11.1; P < .001). NYHA class improved, with class II patients increasing from 55.6% to 62.2% (P < .001). Mean HF decompensations requiring intravenous diuretics decreased from 1.34 (SD: 1.1) in the preceding year to 0.65 (SD: 1.3) during follow-up. Non-HF cardiovascular hospitalizations decreased from 0.98 (SD: 1.4) to 0.39 (SD: 1.0). Vericiguat was discontinued in 13.4% of patients, primarily due to symptomatic hypotension (49.4%). Higher baseline NT-proBNP (per 1000-pg/ml increase) independently predicted discontinuation (OR: 1.06; 95% CI: 1.03-1.08; P < .001). CONCLUSIONS: Vericiguat added to optimized quadruple therapy was associated with reverse remodelling, reduced NT-proBNP, improved functional class, and a numerical reduction in HF-related events in real-world HFrEF patients. These findings confirm the clinical utility and safety of vericiguat in routine practice.
dc.language.iso eng
dc.publisher OXFORD UNIV PRESS
dc.rights Atribución/Reconocimiento 4.0 Internaciona
dc.rights.uri https://creativecommons.org/licenses/by/4.0/deed.es *
dc.subject.mesh Aged
dc.subject.mesh Female
dc.subject.mesh Humans
dc.subject.mesh Male
dc.subject.mesh Follow-Up Studies
dc.subject.mesh Heart Failure/drug therapy/physiopathology/epidemiology
dc.subject.mesh Prospective Studies
dc.subject.mesh Registries
dc.subject.mesh Spain/epidemiology
dc.subject.mesh Stroke Volume/physiology/drug effects
dc.subject.mesh Time Factors
dc.subject.mesh Treatment Outcome
dc.subject.mesh Ventricular Function, Left/physiology/drug effects
dc.title One-year multicenter prospective real-world study of vericiguat effectiveness and safety in Spain
dc.type info:eu-repo/semantics/article 
dc.identifier.pmid 42128540
dc.relation.publisherversion https://academic.oup.com/eschf/article/doi/10.1093/eschf/xvag138/8677720
dc.type.version info:eu-repo/semantics/publishedVersion 
dc.identifier.doi 10.1093/eschf/xvag138
dc.journal.title ESC HEART FAILURE


Ficheros en el ítem

Este ítem aparece en la(s) siguiente(s) colección(ones)

Mostrar el registro sencillo del ítem

Atribución/Reconocimiento 4.0 Internaciona Excepto si se señala otra cosa, la licencia del ítem se describe como Atribución/Reconocimiento 4.0 Internaciona

Buscar en DSpace


Búsqueda avanzada

Listar

Mi cuenta